Company: ACBM
Filing Date: 2025-07-23
Form Type: 10-Q
Source: 0001640334-25-001279
Chunk: 14

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-23
Form: 10-Q
Item: Item 1
Chunk 14
---
2023  2024  2023              Revenues $-  $-  $-  $-                  Operating expenses                Selling, general and administrative  9,086   1,316,425   19,384   2,799,991 Research and development  -   1,878,275   -   4,398,275 Total operating expenses  9,086   3,194,700   19,384   7,198,266                  Loss from operations  (9,086)  (3,194,700)  (19,384)  (7,198,266)                 Other expense                Interest expense - related party  1,057   789   2,011   1,577 Total other expenses  1,057   789   2,011   1,577                  Loss before income tax expense  (10,143)  (3,195,489)  (21,395)  (7,199,843)Income tax expense  -   -   -   - Net loss $(10,143) $(3,195,489) $(21,395) $(7,199,843)                 Basic and diluted loss per share of common stock $(0.00) $(0.05) $(0.00) $(0.12)                 Weighted average number of shares of common stock outstanding  60,042,000   60,042,000   60,042,000   60,042,000 

The accompanying notes are an integral part of these unaudited financial statements.

 5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity (Deficit)

(Unaudited)

For the Three and Six months ended June 30, 2024

              Additional     Total   Preferred Stock  Common Stock   Paid in   Accumulated   Stockholders'    Shares    Amount    Shares    Amount    Capital    Deficit   Deficit                       Balance, December 31,